Table 1.
Summary of efficacy and side effects of RT in patients with NFPA
| RT Type | No of studies | Patients | Dose (Gy), median | Follow-up (median, months) | Tumor control (%) | New Hypopituitarism (%) | Visual defects (%) | Brain radionecrosis (%) | Second brain tumor (%) |
|
SRS type: GK |
19 | 1716 | 16 | 46.6 | 95 (88-97) |
22 | 2.9 (0–7.9) | 0-<1 | 0 |
| CK | 1 | 100 | 7x3 fr/5x5 fr | 36 | 98 at 3 y | 4 | 1 | 0 | 0 |
| LINAC | 3 | 149 | 45 | 48-84 | 98-100 | 10.1 | 0-1.4 | 0-2.8 | 0 |
| CRT | 3 | 406 | 45.5 | 101 | 89 at 10y (87 – 93) |
23 | 0-1 | 0-1 | 0-2 at 10-20y* |
| FSRT | 6 | 320 | 45-54 | 54 | 95.4 | 15.5 | 1.7 (0-5) | 0 | 0.3 |
Legend. The results are expressed in weighted means calculated from the published studies; SRS = stereotactic radiosurgery; CRT = conventional fractionated radiotherapy; FSRT = fractionated stereotactic radiotherapy; GK = gamma knife radiosurgery; LINAC = linear accelerator radiosurgery; CK = Cyberknife radiosurgery; y = years; fr = fractions; * actuarial rates in 331 various pituitary adenomas (17).